Rated 1.71 | 175 Views
By NewsInfusion
Rated 0.00 | 5 Views
By ccaproni
Rated 1.00 | 57 Views
By MultiVu
Novartis' Sullivan on Cross-border Dealmaking
Rated 0.00 | 21 Views
By Thedealvideo
Clinical Symptoms Equine Influenza
Rated 3.30 | 234 Views
Affiliate Submitter: dano2607
Rated 4.50 | 53 Views
Affiliate Submitter: americanlung
Rated 4.09 | 374 Views
Affiliate Submitter: BrainPOPLat
México Prepara Laboratorios Para Identific...ar Virus De Influenza
Rated 0.00 | 4 Views
Affiliate Submitter: Lainfluenzamx
Rated 1.72 | 104 Views
By MultiVu
Safe Your Self from Influenza with Mask
Rated 3.71 | 681 Views
By satavut1972
Rated 3.43 | 162 Views
By jason gaya
Canadá: Circula Virus De Influenza Porcina...Jamás Visto En México
Rated 4.09 | 389 Views
Affiliate Submitter: PepitosGroup
Mira Esto Es Muy Importante De La Influenz...a Porcina
Rated 0.00 | 8 Views
By gamaxp
Influenza A H1N1 Bioseguridad Para Médicos
Rated 0.00 | 137 Views
Enrique Peña Nieto - Conferencia Influenza
Rated 0.00 | 63 Views
By robalo32
Spot T.V. Medidas De Prevención Influenza
Rated 0.90 | 56 Views
Affiliate Submitter: gobiernofederal
English
Novartis has broken ground on construction of the first cell culture-derived influenza vaccines manufacturing plant in the United States. Once completed, the Holly Springs, North Carolina facility is expected to annually produce up to 50 million doses of seasonal trivalent flu vaccines or up to 150 million monovalent doses within six months of a pandemic declaration.
Completion of the facility is expected in late 2009, and following validation and FDA approval, initial vaccine production at the site is anticipated for 2011.
An investment of approximately $600 million, which includes a $220 million grant from the US Department of Health and Human Services is planned to complete the Holly Springs facility. In addition to the significant investment in plant construction and equipment, the site will bring more than 350 new job opportunities to the area, including entry level, technicians, supervisors and management.